Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17925127 | 0.94 | GPR119 (0.54) | GPR119CYP11B2KCNJ1HIF1A | |
| SCHEMBL4515684 | 0.86 | GPR119 (0.64) | GPR119ALDH1A1 | |
| SCHEMBL16432766 | 0.85 | KCNJ1 (0.49) | KCNJ1KCNH2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL21698765 | 0.84 | CYP11B2 (0.51) | GPR119CYP11B2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL30327742 | 0.82 | CYP11B2 (0.49) | GPR119CYP11B2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL17925118 | 0.82 | GPR119 (0.51) | GPR119CYP11B2KCNJ1CYP2C19 | |
| SCHEMBL30329041 | 0.81 | CYP11B2 (0.52) | GPR119CYP11B2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL17925041 | 0.81 | GPR119 (0.52) | GPR119CYP11B2KCNJ1ALDH1A1CYP3A4 | |
| SCHEMBL20468949 | 0.80 | CYP11B2 (0.53) | GPR119CYP11B2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL17925046 | 0.80 | GPR119 (0.54) | GPR119CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027625-B1 | SPIRO-FUSED DERIVATIVES OF PIPERIDINE USEFUL FOR THE TREATMENT OF INTER ALIA HYPERTENSION AND ACUTE OR CHRONIC HEART FAILURE | MERCK SHARP & DOHME (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9751881-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160207922-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME CORP. (US) | 2016-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207922-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | GPR119 1088/4885CYP11B2 1375/4885KCNJ1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.